Clinical trial

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

NCT00466284

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Tarceva (erlotinib) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Phase II Trial of Tarceva in Patients With Non-Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2006-01-01

PhasePHASE2

Conditions

Non-Small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

Tarceva (erlotinib)DRUG

Sponsors & collaborators

Grupo Gallego de Cancer de Pulmonlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00466284 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.